Innovative Drug Discovery and Development
Formerly the John S. Dunn Gulf Coast Consortium for Chemical Genomics (GCC CG) which was formed in 2003, the Consortium for Innovative Drug Discovery and Development (GCC IDDD) is a research consortium focused on providing support for Houston/Galveston scientists in advancing their therapeutics discoveries through development to the clinic. IDDD support includes collaborative networking and joint funding opportunities, shared core resources, and educational programs.
Artificial Intelligence Shakes Up Drug Discovery
The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.
Thank you to everyone who helped make our Kickoff Mini-Symposium a success! For speaker and panel videos, Click Here.
Drug Discovery in Africa
June 5, 2019, 7:30-9:00 AM
Drug discovery research in Africa has lagged that carried out in the more developed nations of the world. Africa is often described as the “next frontier” in the global economy, yet a crippling disease burden continues to choke economic growth on the continent. It is thus vital for Africans to contribute to finding solutions to their health problems, which are not just African health problems but human health problems. Historically Africa has benefited immensely from medicines discovered and developed elsewhere. It is time for Africa to reciprocate and in the process contribute to the creation of science jobs in Africa as well as confront afro-pessimism and debunk the myth that Africa is not, and cannot be, a source of health innovation.
Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed)
09 June, 2019 – 14 June, 2019
ResMed is a week-long graduate/professional-level course providing an accelerated program for medicinal chemists, biologists and other industrial and academic scientists who choose to broaden their knowledge of the drug discovery and development process. The course concentrates on the fundamentals of drug discovery spanning initial target validation through clinical development. The course is taught by distinguished faculty from industry and academia and provides ample opportunity for discussion and networking.
Registration Deadline: 31 March 2019
Contact Name: Neal Connors
Contact E-mail: email@example.com
Contact Number: (973)408-3794
Save the Date:
Innovative Drug Discovery and Development Round Table Series Kickoff, June 13, 4 pm
BRC, Rm 1003
Please plan to join us for the first of our new monthly program focused on drug development topics and resources. This interactive series kickoff will be focused on the importance of the Target Product Profile (TPP) and considerations for its development for therapeutics projects. Speakers leading this discussion will include Brett Cornwell, Executive Director for Texas A&M Technology Commercialization and Philip Jones, VP, Therapeutics Discovery, MDA Cancer Center; and Head, Drug Discovery, Institute for Applied Cancer Science (IACS). The event will take place at 4 pm in the Bioscience Research Collaborative, room 1003. A networking reception will follow.
Save the Date:
MD Anderson Cancer Center and Baylor College of Medicine 2019 Joint Symposium:
DRUG DEVELOPMENT, June 20, 2019, 8:00 AM – 5:30 PM
Keynote Speaker – Roy S. Herbst, MD. PhD, Chief of Medical Oncology and Associate Director for Translational Research, Yale Cancer Center
Speakers Include: Yannick Bulliard, Immatics; Eric Chang, BCM; Diana Chow, Univ of Houston; Teemu Junttila, Genentech; Albert Koong, MDACC; Yan Lan, EMD Serono; Tim Palzkill, BCM; Katharina Schlacher, MDACC; Nicholas Simmons, BCM; Vivek Subbiah, MDACC; Yuting Sun, MDACC; Trey Westbrooke, BCM; Nicholas Young, BCM
Outsourcing in Clinical Trials Texas 2019, September 11-12, 2019:
Save the Date: